The Real World Evidence On Treatment Patterns, Effectiveness, And Safety Of Drugs For Stroke Prevention In Nonvalvular Atrial Fibrillation Patients In Korea
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Antiplatelets (Primary) ; Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Nov 2019 Status changed from recruiting to completed.
- 22 May 2019 Status changed from active, no longer recruiting to recruiting.
- 08 May 2019 Planned End Date changed from 18 Jun 2019 to 20 Nov 2019.